Delving into the blood samples of over 4,000 participants devoid of clinically diagnosed heart disease, the researchers meticulously correlated protein abundance with documented family histories of cardiovascular events among parents or siblings. The resultant data set revealed 38 distinct proteins elevated in those with familial risk. These proteins predominantly relate to inflammatory pathways and lipid metabolism—two critical domains in the pathogenesis of coronary atherosclerosis. This discovery underscores a previously underappreciated biochemical signature that transcends standard clinical risk factors.

Among the proteins of interest, follistatin and cathepsin D emerged as significantly upregulated in individuals with a hereditary predisposition to coronary artery disease, irrespective of traditional risk determinants such as blood pressure, cholesterol levels, or lifestyle factors. Follistatin, known for its role in opposing transforming growth factor-beta signaling, and cathepsin D, a lysosomal enzyme implicated in extracellular matrix remodeling and apoptosis, may serve as pivotal biomarkers linking genetic inheritance to pathological vascular remodeling.

The study leveraged data from the Swedish CArdioPulmonary bioImage Study (SCAPIS), an extensive population cohort featuring comprehensive health assessments including advanced coronary computed tomography (CT) angiography. The rich integration with national health registers, notably the Swedish Multigenerational Register, enabled the team to definitively associate familial history with coronary atherosclerosis severity, quantitatively expressed by the number of diseased coronary vessel segments. This structural hallmark provided a tangible link between protein expression patterns and the anatomical burden of disease.

Intriguingly, the investigators identified LDL receptor and PECAM1 among the proteins whose plasma levels bore a heightened relationship to the extent of coronary artery disease specifically in those with a hereditary risk. The LDL receptor is central to cholesterol homeostasis, mediating endocytosis of low-density lipoproteins, while PECAM1 plays a critical role in endothelial cell function and intercellular junction integrity. Their elevated presence may reflect a compensatory or pathological response within the vascular endothelium, potentiating atherosclerotic progression.

These findings suggest that hereditary atherosclerosis is characterized by a distinct, biologically coherent protein signature, offering new explanatory avenues for why certain individuals develop premature coronary artery disease despite engaging in heart-healthy behaviors. This biological pattern may redefine risk stratification, augmenting beyond traditional clinical metrics to encompass molecular diagnostics.

To unravel causality within these protein-disease associations, the research employed sophisticated genetic analyses, including Mendelian randomization techniques. This approach provided evidence implicating specific proteins—follistatin, PCSK9, and PECAM1—as not mere bystanders but active contributors to the pathogenesis of myocardial infarction. PCSK9, a well-known regulator of LDL receptor degradation, has already been targeted pharmacologically, validating the clinical relevance of these molecular insights.

The broader implications of this study extend into the realm of precision cardiovascular medicine. By delineating the molecular architectures linked to both hereditary and non-hereditary coronary artery disease, these insights lay groundwork for novel therapeutic targets and personalized risk prediction models. Future interventions might one day modulate these protein pathways to mitigate inherited susceptibility to atherosclerosis.

Clinical translation of these findings could revolutionize how cardiovascular risk is assessed, particularly in asymptomatic individuals with family histories suggestive of early-onset disease. Integrating plasma proteomics into routine cardiovascular screening could identify high-risk patients earlier, enabling timely preventive strategies that transcend lifestyle modification and standard pharmacotherapy.

Furthermore, this research highlights the importance of large-scale population studies like SCAPIS that combine comprehensive phenotyping with genetic and molecular analyses. Such integrative datasets empower researchers to disentangle complex disease etiologies and uncover subtle biological signals obscured in smaller cohorts.

The Karolinska Institutet-led study exemplifies collaborative innovation within modern biomedical research, uniting clinicians, geneticists, and molecular biologists to tackle the pressing public health challenge of coronary artery disease. By illuminating the molecular signature of hereditary risk, it opens a new vista for both mechanistic understanding and clinical management of cardiovascular disorders.

As the global burden of cardiovascular diseases continues to rise, identifying individuals genetically predisposed to early atherosclerosis assumes critical importance. This study’s demonstration of a specific plasma protein pattern heralds a paradigm shift toward molecularly informed cardiovascular risk assessment and intervention, promising to reduce the incidence of heart attacks and improve long-term outcomes.

In sum, the research presents compelling evidence that common proteins associated with inflammation, lipid metabolism, and vascular function form a distinct proteomic profile linked to inherited risk for early-onset coronary heart disease. These novel biomarkers, some causatively related to disease mechanisms, deepen our understanding of the biological underpinnings of atherosclerosis and pave the way for precision medicine approaches that can preempt clinical disease before irreversible arterial damage ensues.

Subject of Research: People

Article Title: Plasma Protein Profile Associated With a Family History of Early-Onset Coronary Heart Disease

News Publication Date: 7-Nov-2025

Web References:
https://www.ahajournals.org/doi/10.1161/CIRCGEN.124.005220

References:
Wahrenberg, A., Lind, L., Åberg, N., Häbel, H., Ström, M., Mälarstig, A., Magnusson, P.K.E., Halkola, R.-K., Bergström, G., Engström, G., Hagström, E., Jernberg, T., Söderberg, S., Östgren, C.J., Svensson, P. (2025). Plasma Protein Profile Associated With a Family History of Early-Onset Coronary Heart Disease. Circulation: Genomic and Precision Medicine. https://doi.org/10.1161/CIRCGEN.124.005220

Keywords: Cardiovascular disorders, hereditary atherosclerosis, plasma proteins, coronary heart disease, inflammation, lipid metabolism, proteomics, genetic risk, precision medicine

Coronary artery calcium is widely regarded as a robust indicator of coronary artery disease (CAD) risk, precisely quantifying the extent of calcified atherosclerotic plaque within the coronary vessels. These calcifications occur as cholesterol-rich plaques within the arterial walls mature and undergo a process of mineralization, rendering them visible through non-invasive imaging techniques such as computed tomography (CT). The greater the calcium burden detected, the higher the individual’s risk of obstructive coronary lesions potentially leading to ischemic events. Consequently, a CAC score of zero has traditionally been interpreted as evidence of the absence of clinically significant coronary atherosclerosis, signaling a low likelihood of imminent cardiac events.

Coronary atherosclerosis develops when lipids infiltrate the intimal layer of coronary arteries, triggering an inflammatory cascade that culminates in plaque formation. These plaques, composed of fibrous tissue, lipids, and inflammatory cells, progressively narrow the arterial lumen, compromising myocardial perfusion. A critical pathological event occurs when a plaque ruptures, exposing thrombogenic material to the bloodstream, rapidly precipitating thrombus formation. This occlusive event often manifests clinically as unstable angina or an acute myocardial infarction, contributing significantly to cardiovascular morbidity and mortality globally.

Using cardiac PET/CT scans as part of routine clinical evaluation in a cohort deemed at risk for CAD, the Intermountain Health team stratified over 40,000 patients based on their CAC scores. Among this extensive population, nearly 8,000 individuals exhibited no detectable coronary artery calcium, while the majority showed varying degrees of calcification. The study followed these subjects over a five-year period, meticulously tracking all-cause mortality to assess the prognostic value of CAC beyond traditional cardiovascular endpoints.

Statistical analysis revealed that individuals with any measurable CAC faced a two to threefold increased risk of death from all causes when compared to those with a CAC score of zero. Interestingly, the increased mortality associated with elevated CAC extended well beyond cardiovascular death, as approximately 75% of deaths in the CAC-positive group were attributed to non-cardiac conditions. This phenomenon underscores an unanticipated correlation between coronary calcification and generalized systemic health risks, prompting a paradigm shift in how CAC should be interpreted within clinical practice.

Dr. Jeffrey L. Anderson, the principal investigator and distinguished clinical researcher at Intermountain Health, emphasized the novelty of these findings. He posited that while the absence of CAC has long been regarded as indicative of optimal heart health, its predictive power might extend into broader dimensions of health status. The hypothesis emerging from this research suggests a possible systemic relationship whereby atherosclerotic burden in coronary arteries reflects the presence of generalized vascular pathology or even impairs intrinsic protective mechanisms such as immune surveillance mechanisms against malignancies.

One plausible mechanistic explanation for the observed associations involves the concept of systemic atherosclerosis, where calcified plaques in coronary arteries mirror similar pathological processes occurring within vascular beds throughout the body. This widespread vascular disease could contribute to multi-organ dysfunction, predisposing individuals to conditions beyond cardiovascular pathology. Furthermore, chronic inflammation linked to atherosclerosis may have deleterious effects on immune competence, potentially facilitating oncogenesis or other systemic illnesses.

This study’s retrospective design entailed rigorous evaluation of patient electronic health records, incorporating imaging data and subsequent mortality outcomes to paint a comprehensive picture of CAC’s prognostic significance. The utilization of PET/CT stress testing allowed for precise quantification of calcified plaque burden and provided a valuable tool for risk stratification that surpasses traditional risk factor assessments alone, such as lipid profiles or blood pressure measurements.

While these results pave the way for fascinating clinical and scientific exploration, several fundamental questions remain unresolved. Primarily, the mechanisms underlying the heightened risk of non-cardiovascular death in patients with elevated CAC are not yet delineated. This ambiguity highlights the need for prospective studies focusing on specific causes of mortality and examining potential confounding variables such as concurrent comorbidities, lifestyle factors, and genetic predispositions.

Looking forward, the Intermountain research team aims to deepen the investigation into the non-cardiovascular mortality causes among patients with coronary calcification. Understanding these pathways could unlock new interventions targeting systemic vascular health, immune function, and inflammation, possibly permitting earlier identification and management of patients at risk for a spectrum of life-threatening diseases.

The implications of these findings extend beyond cardiology, hinting at an integrative biomarker that encapsulates an individual’s overall health resilience. Clinicians might soon consider CAC scoring not only as a tool to predict heart attack risk but also as part of a holistic assessment that informs prognosis related to cancer, chronic infections, and other systemic disorders. Such an approach could transform preventive medicine paradigms and personalize healthcare strategies more effectively.

At the American Heart Association Scientific Sessions 2025, where this research was first unveiled, enthusiasm abounded for the potential clinical applications of coronary artery calcium scoring. The study represents a critical step in reimagining cardiovascular imaging biomarkers through a more expansive lens that crosses traditional disciplinary boundaries. It invites a future where quantifiable vascular imaging data could guide multifaceted health interventions with widespread impact.

Ultimately, the discovery that the absence of coronary artery calcium serves as a predictor of enhanced longevity and reduced vulnerability to myriad medical conditions is a compelling call for the medical community to revisit existing paradigms. As the research community embarks on unraveling the biological basis of this association, patients might one day benefit from tailored diagnostic insights that foresee and circumvent fatal illnesses beyond the heart.

Subject of Research: People
Article Title: Coronary Artery Calcium Score Predicts Broader Health Outcomes Beyond Cardiovascular Disease
News Publication Date: November 8, 2025
Image Credits: Intermountain Health
Keywords: Heart disease, Acute myocardial infarction, Coronary artery calcium, Cardiovascular risk, Atherosclerosis, Immune surveillance, Non-cardiovascular mortality, PET/CT imaging, Coronary plaque, All-cause mortality